Perturbed glucose metabolism: Insights into multiple sclerosis pathogenesis

Frontiers in Neurology

Volumn 5, Issue NOV, 2014, Pages 1-20

  Mathur, Deepali ^a,d   Rodas, Gerardo Lopez ^a,d   Casanova, Bonaventura ^b,d   Marti, Maria Burgal ^c,d  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^d INSTITUTE OF PHYSICS   (India)

Author keywords

Brain glucose metabolism; Cell specific mechanisms; Mitochondrial defects; Multiple sclerosis; Neurodegenerative diseases

Indexed keywords

GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; GLUCOSE TRANSPORTER 5; GLUCOSE TRANSPORTER 6; GLUCOSE TRANSPORTER 7; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MEMBRANE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; TRIOSEPHOSPHATE ISOMERASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN METABOLISM; CARBOHYDRATE METABOLISM; CITRIC ACID CYCLE; DEGENERATIVE DISEASE; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY BALANCE; ENERGY METABOLISM; GLIA CELL; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; HUNTINGTON CHOREA; MULTIPLE SCLEROSIS; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PENTOSE PHOSPHATE CYCLE; PROTEIN EXPRESSION; SHORT SURVEY; VASCULAR ENDOTHELIUM;

EID: 84910648888     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2014.00250     Document Type: Short Survey

References (49)

1. Bae, B., Makoto R, Hara., Matthew, B., Cascio, Cheryl L., Wellington, Michael R., Hayden, Christopher A., Ross, Hyo Chol Ha., Xiao-Jiang, Li., Solomon, H. Snyder., and Akira, Sawa. (2006). Mutant Huntingtin: Nuclear translocation and cytotoxicity mediated by GAPDH. PNAS 103(9), 3405-3409. doi: 10.1073/pnas.0511316103
2. Bauer, H. (1956). Biochem Z., 327, 491.
3. Birnbaum, MJ., Haspel, HC., and Rosen, OM. (1986). Cloning and characterization of a cDNA encoding the rat brain glucose transporter protein. Proc. Natl. Acad. Sci. U.S.A. 83, 5784-5788. doi:10.1073/pnas.83.16.5784
4. Bjartmar, C., Wujek, JR., Trapp, BD. (2003). Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. Journal of the Neurological Sciences 206(2), 165-171.
5. Blalock, EM., Geddes, JW., Chen, KC., Porter, NM., Markesbery, WR., Landfield, PW. (2004). Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A. 101, 2173-2178.
6. Bondy, CA., Lee, WH., and Zhou, J. (1992). Ontogeny and cellular distribution of brain glucose transporter gene expression. Mol. Cell. Neurosci. 3, 305-314.
7. Broadwater, L., Pandit, A., Azzam, S., Clements, R., Vadnal, J., Sulak, M., Yong, VW., Freeman, EJ., Gregory, RB., and McDonough, J. (2011). Analysis of the Mitochondrial Proteome in Multiple Sclerosis Cortex. Biochim Biophys Acta. 1812(5), 630-641. doi: 10.1016/j.bbadis.2011.01.012.
8. Brooks, WM., Lynch, PJ., Ingle, CC., et al. (2007). Gene expression profiles of metabolic enzyme transcripts in Alzheimer's disease. Brain Res. 1127, 127-135.
9. Burke D. (1983). Demyelination in optic neuritis and its effects on the visual evoked potential. Aust. J. Ophthalmol 11, 341-345. doi: 10.1111/j.1442-9071.
10. Confavreux, C., Vukusic, S., Moreau, T., Adeleine, P. (2000). Relapses and progression of disability in multiple sclerosis. N Engl J Med. 343, 1430-8.
11. Chandrasekaran, K., Giordano, T., Brady, DR., Stoll, J., Martin, LJ., Rapoport, SI. (1994). Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. Brain Res Mol Brain Res. 24, 336-340.
12. Diab, A., Deng, C., Smith, J.D., Hussain, R.Z., Phanavanh, B., Lovett-Racke, A.E., Drew, P.D., Racke, M.K. (2002). Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168, 2508-2515. doi: 10.4049/jimmunol.168.5.2508
13. Duvanel, C.B., Honegger, P., Pershadsingh, H., Feinstein, D., Matthieu, J.M. (2003). Inhibition of glial cell proinflammatory activities by peroxisome proliferator activated receptor gamma agonist confers partial protection during antimyelin oligodendrocyte glycoprotein demyelination in vitro. J. Neurosci. Res. 71, 246-255.
14. Dutta, R., McDonough, J., Yin, X., et al. (2006). Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Annals of Neurology 59(3), 478-489. doi:10.1002/ana.20736.
15. Ervenich P,. 1952. Atrzl. Prax., Lpz., 4, 2.
16. Ferguson, B., Matyszak, MK., Esiri, MM., Perry, VH. (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120(3), 393-399. doi: 10.1093/brain/120.3. 393.
17. Fisher, MT., Sharma, R., Lim, JL., Haider, L., et al. (2012). NADPH oxidase expression in active MS lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 135, 886-899.
18. Gould, GW., and Holman, GD. (1993). The glucose transporter family: Structure, function and tissue-specific expression. Neurosci Lett. 97: 209-214. doi:
19. Henneman, DH., Altschule, MD., Goncz, RM., and Alexander, L,. (1954). A.M.A. Arch. Neurol. Psychiat. 72, 688.
20. Howarth, C., et al. (2012). Updated energy budgets for neural computation in the neocortex and cerebellum. J. Cereb. Blood Flow Metab. 32, 1222-1232.
21. Iñarrea, P., Alarcia, R., Alava, MA., Capablo, JL., Casanova, A., Iñiguez, C., Iturralde, M., Larrodé, P., Martín, J., Mostacero, E., Ara, JR. (2013). Mitochondrial Complex Enzyme Activities and Cytochrome c Expression Changes in Multiple Sclerosis. Mol Neurobiol. Doi: 10.1007/s12035-013-8481-z.
22. Jeanes, AL., and Cumings, JN., 1958. Confin. neurol. (Basel) 18, 397.
23. Jones, HH., Jones, HH Jr., and Bunch, LD.,1950. Ann. intern. Med. 33, 831.
24. Kasaniki, MA., Cairns, MT., Davies, A., Gardiner, RM., and Baldwin, SA. (1987). Identification and characterization of the glucose transport protein of the bovine blood-brain barrier. Biochem. J. 247, 101-108.
25. Kety, SS. (1957). The general metabolism of the brain in vivo. In: Richter D, editor. Metabolism of the nervous system. London: Pergamon. pp. 221-237.
26. Kölln, J., Zhang, Y., Thai, G., Demetriou, M., Hermanowicz, N., Duquette, P., Noort, S., and Qin, Y. (2010). Inhibition of Glyceraldehyde-3-Phosphate Dehydrogenase Activity by Antibodies Present in the Cerebrospinal Fluid of Patients with Multiple Sclerosis. The Journal of Immunology 185, 1968-1975. doi: 10.4049/jimmunol.0904083.
27. Kölln, J., Ren, HM., Da, RR., Zhang, Y., Spillner, E., Olek, M., Hermanowicz, N., Hilgenberg, LG., Smith, MA., Noort, S., and Qin, Y. (2006). Triosephosphate Isomerase-and Glyceraldehyde-3-Phosphate Dehydrogenase-Reactive Autoantibodies in the Cerebrospinal Fluid of Patients with Multiple Sclerosis. The Journal of Immunology 177, 5652-5658. doi: 10.4049/jimmunol.177.8.5652.
28. L. Bö, J. J. G. Geurts, S. J. Mörk and P. van der Valk. (2006). Gray matter pathology in multiple sclerosis, Acta Neurologica Scandinavica, 113: 48-50. doi: 10.1111/j.1600-0404.
29. Lin, J., Diamanduros, A., Chowdhury, SA., Scelsa, S., Latov, N., Sadiq, SA. (2009). Specific electron transport chain abnormalities in amyotrophic lateral sclerosis. J Neurol. 256(5), 774-82. doi: 10.1007/s00415-009-5015-8.
30. Lu, F., Selak, M, O'Connor J., et al. (2000). Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. Journal of the Neurological Sciences 177(2), 95-103.
31. Mahad, D., Ziabreva, I., Lassmann, H., and Turnbull, D. (2008). Mitochondrial defects in acute multiple sclerosis lesions. Brain 131, 1722-1735. doi: 10.1093/brain/awn105.
32. Maher, F., Vannucci, SJ., and Simpson, IA. (1994). Glucose transporter proteins in brain. FASEB J. 8: 1003-1011. doi:
33. Mazzola, JL., and Sirover, MA. (2001). Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts. Journal of Neurochemistry 76, 442-449. doi: 10.1046/j.1471-4159.
34. McArdle, B., Mackenzie, ICK., and Webster, GR. (1960). Studies on intermediate carbohydrate metabolism in Multiple Sclerosis. J. Neurol. Neurosurg. Psychiat., 23, 127. doi: 10.1136/jnnp.23.2.127.
35. Morgello, S., Uson, RR., Schwartz, EJ., and Haber, RS. (1995). The human blood526 brain barrier glucose transporter (GLUT1) is a glucose transporter of gray matter astrocytes. Glia 14: 43-54. doi:
36. Nehlig, A. (2004). Brain uptake and metabolism of ketone bodies in animal models. Prostaglandins Leukot. Essent. Fatty Acids. 70, 265-275.
37. Pandit, A., Vadnal, J., Houston, S., Freeman, E., McDonough, J. (2009). Impaired Regulation of Electron Transport Chain Subunit Genes by Nuclear Respiratory Factor 2 in Multiple Sclerosis. J. Neurol. Sci. 279, 14-20. 10.1016/j.jns.2009.01.009.
38. Regenold, WT., Phatak, P., Makley, MJ., Stone, RD., and Kling, MA. (2008). Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression. J Neurol Sci. 275(1-2), 106-112. doi: 10.1016/j.jns.2008.07.032.
39. Royds, JA., Timperley, WR., Taylor, CB. (1981). Levels of enolase and other enzymes in the cerebrospinal fluid as indices of pathological change. Journal of Neurology, Neurosurgery, and Psychiatry 44, 1129-1135. doi:10.1136/jnnp.44.12.1129
40. Safavizadeh, N., Rahmani, SA., and Zaefizadeh, M. (2013). Investigation of cytochrome c oxidase gene subunits expression on the Multiple sclerosis. Indian J Hum Genet. 19(1), 18-25. doi: 10.4103/0971-6866.112879.
41. Schulze, H., Schuler, A., Stüber, D., Döbeli, H., Langen, H., and Huber, G. (1993). Rat brain glyceraldehyde-3-phosphate dehydrogenase interacts with the recombinant cytoplasmic domain of Alzheimer's ß-amyloid precursor protein. J Neurochem 60, 1915-1922. doi:10.1111/j.1471-4159.
42. Senatorov, VV., Charles, V., Reddy, PH., Tagle, DA., and Chuang, D. (2003). Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington's disease. Molecular and Cellular Neuroscience. 22, 285-297. doi: 10.1016/S1044-7431(02)00013-1.
43. Simonian, NA., Hyman, BT. (1994). Functional alterations in Alzheimer's disease: selective loss of mitochondrial-encoded cytochrome oxidase mRNA in the hippocampal formation. J Neuropathol Exp Neurol. 53, 508-512.
44. Smith, KJ., Lassmann, H. (2002). The role of nitric oxide in multiple sclerosis. Lancet Neurology 1(4), 232-241.
45. Soucek, T., Cumming, R., Dargusch, R., Maher, P., and Schubert, D. (2003). The Regulation of Glucose Metabolism by HIF-1 Mediates a Neuroprotective Response to Amyloid Beta Peptide. Neuron 39, 43-56. http://dx.doi.org/10.1016/S0896-6273(03)00367-2.
46. Szalardya, L., Zadoria, D., Tanczosb, E., Simuc, M., Bencsika, K., Vecseia, d, L., Klivenyi, P. (2013). Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis. Neuroscience Letters 554, 131-134. http://dx.doi.org/10.1016/j.neulet.2013.08.069.
47. Takasaki, Y., Kaneda, K., Matsushita, M., Yamada, H., Nawata, M., Matsudaira, R., Asano, M., Mineki, R., Shindo, N., and Hashimoto, H. (2004). Glyceraldehyde 3-phosphate dehydrogenase is a novel autoantigen leading autoimmune responses to proliferating cell nuclear antigen multiprotein complexes in lupus patients. Int. Immunol 16, 1295-1304. doi: 10.1093/intimm/dxh131.
48. s BØ., Rodenburg, RJ., et al. (2009). Enhanced number and activity of mitochondria in multiple sclerosis lesions. Journal of Pathology 219(2), 193-204. doi: 10.1002/path.2582.
49. Zhang, Y., Da, RR., Guo, HM., Ren Hilgenberg, LG., Sobel, RA., Tourtellotte, WW., Smith, MA., Olek, MK., Gupta, S., et al. (2005). Axon reactive B cells clonally expanded in the cerebrospinal fluid of patients with multiple sclerosis. J. Clin. Immunol. 25, 254-264. doi: 10.1007/s10875-005-4083-5.